Capricor Therap (CAPR) Stock Price, Quote & News

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1755

Website: www.capricor.com

Address:

10865 Road to the Cure, Suite 150, San Diego, United States

Elon_Trumpet Feb. 26 at 11:12 AM

$CAPR nearing that market cap cross with $SRPT

0 · Reply

Skyhigh77 Feb. 26 at 11:04 AM

$CAPR https://www.wsj.com/opinion/vinay-prasad-fda-drug-approvals-disc-medicine-regenxbio-marty-makary-8488f514?st=P7AvEn&reflink=desktopwebshare_permalink Let’s get this mother f out of FDA… he has caused more harm then anyone that’s held the seat and will be doing that even more if something isn’t done soon…the Moderna debacle was probably the start of the end of Vinay Prasad at CBER.. would be super bullish for the entire sector if something happened soon…

0 · Reply

hegdaom Feb. 26 at 11:04 AM

$CAPR

0 · Reply

hegdaom Feb. 26 at 11:04 AM

$CAPR

0 · Reply

hegdaom Feb. 26 at 11:04 AM

$CAPR

0 · Reply

Donkeykong87 Feb. 26 at 10:24 AM

$CAPR Bears returning to this board = WINNING!!!!

0 · Reply

dzetu Feb. 26 at 10:14 AM

$CAPR We don't remember investing in you.

0 · Reply

IEatBearsForBreakfast Feb. 26 at 9:45 AM

$CAPR Good morning Capricor family, let’s keep chugging along

0 · Reply

Lion0fWallSt Feb. 26 at 9:19 AM

$ATOS $CAPR $SRPT $TTD Poppy shorts it to buy $PLTR , we have acquired 8,600 shares.

1 · Reply

Rascal7777777 Feb. 26 at 8:28 AM

$SRPT $CAPR $ATOS everyone report this mf sick fuck. Rot In Hell.

1 · Reply

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript

Dec 7, 2025, 8:21 AM EST - 2 months ago

Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel

Dec 6, 2025, 1:18 AM EST - 2 months ago

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript

Dec 4, 2025, 4:01 PM EST - 2 months ago

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Dec 3, 2025, 2:21 PM EST - 3 months ago

Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say

Dec 3, 2025, 9:23 AM EST - 3 months ago

Capricor Therapeutics Duchenne Treatment Shows Strong Heart And Muscle Results In Trial

Dec 3, 2025, 7:44 AM EST - 3 months ago

Capricor's muscle disorder cell therapy succeeds in late-stage study

Nov 24, 2025, 1:49 PM EST - 3 months ago

Martin Shkreli Takes Aim At Capricor — Stock Sinks

Nov 10, 2025, 11:21 PM EST - 3 months ago

Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 9:15 AM EST - 4 months ago

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

Oct 31, 2025, 9:15 AM EDT - 4 months ago

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Oct 3, 2025, 10:45 AM EDT - 5 months ago

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Sep 29, 2025, 3:51 PM EDT - 5 months ago

Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026

Sep 29, 2025, 9:08 AM EDT - 5 months ago

Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway

Sep 25, 2025, 11:07 AM EDT - 5 months ago

Capricor Therapeutics, Inc. - Special Call

Sep 25, 2025, 7:15 AM EDT - 5 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

Sep 13, 2025, 11:35 AM EDT - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Sep 9, 2025, 9:20 AM EDT - 6 months ago

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

Aug 28, 2025, 7:05 PM EDT - 6 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 22, 2025, 10:20 AM EDT - 6 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 18, 2025, 11:35 AM EDT - 6 months ago

Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Conference Call Transcript

Aug 8, 2025, 8:30 AM EDT - 7 months ago

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Aug 6, 2025, 9:00 AM EDT - 7 months ago

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Jul 31, 2025, 8:45 AM EDT - 7 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit - CAPR

Jul 30, 2025, 4:27 PM EDT - 7 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit – CAPR

Jul 30, 2025, 11:07 AM EDT - 7 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

SRPT CABA NGNE NTLA QURE RCKT

Jul 17, 2025, 4:46 PM EDT - 7 months ago

BREAKING: Capricor Therapeutics Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses

Jul 16, 2025, 7:55 PM EDT - 8 months ago

Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm

Jul 14, 2025, 4:14 PM EDT - 8 months ago

Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors

Jul 14, 2025, 7:43 AM EDT - 8 months ago

Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter

Elon_Trumpet Feb. 26 at 11:12 AM

$CAPR nearing that market cap cross with $SRPT

0 · Reply

Skyhigh77 Feb. 26 at 11:04 AM

0 · Reply

hegdaom Feb. 26 at 11:04 AM

$CAPR

0 · Reply

hegdaom Feb. 26 at 11:04 AM

$CAPR

0 · Reply

hegdaom Feb. 26 at 11:04 AM

$CAPR

0 · Reply

Donkeykong87 Feb. 26 at 10:24 AM

$CAPR Bears returning to this board = WINNING!!!!

0 · Reply

dzetu Feb. 26 at 10:14 AM

$CAPR We don't remember investing in you.

0 · Reply

IEatBearsForBreakfast Feb. 26 at 9:45 AM

$CAPR Good morning Capricor family, let’s keep chugging along

0 · Reply

Lion0fWallSt Feb. 26 at 9:19 AM

$ATOS $CAPR $SRPT $TTD Poppy shorts it to buy $PLTR , we have acquired 8,600 shares.

1 · Reply

Rascal7777777 Feb. 26 at 8:28 AM

$SRPT $CAPR $ATOS everyone report this mf sick fuck. Rot In Hell.

1 · Reply

Lion0fWallSt Feb. 26 at 7:50 AM

$SRPT $CAPR $ATOS you guys invested in retarded boys

3 · Reply

DragonAlgo Feb. 26 at 7:21 AM

🐉 $CAPR CALL — DragonAlgo® Signal Contract: CAPR CALL Expiry: 2026-03-20 | Strike: $29.00 | Type: CALL Option Plan (premium): Entry: $2.80 Stop: $2.02 TP1: $3.64 TP2: $4.76 TP3: $6.72 Momentum tape remains active. 🔗 https://dragonalgo.com

0 · Reply

Stonksgoingup Feb. 26 at 6:22 AM

$CAPR 🧐

0 · Reply

BioResearcher Feb. 26 at 5:00 AM

$CPIX $LRMR $CAPR CPIX's drug: Ifetroban is currently under preclinic trial to treat Friedreich ataxia. (FA) 's heart disease. LRMR's drug is for Friedreich ataxia. (FA).

0 · Reply

CAPRuccino Feb. 26 at 3:36 AM

$CAPR

2 · Reply

Bejita Feb. 25 at 11:12 PM

$CAPR still no BLA news ? always at the limit

4 · Reply

Cote0924 Feb. 25 at 10:32 PM

$CAPR Doug announced on today’s ER call he is leaving in 2026. Long time coming. Probably helps Srpt.

1 · Reply

Martinsucks Feb. 25 at 10:03 PM

$CAPR this is down after hours as well? Wtf is fk is going on here.

1 · Reply

Groggok Feb. 25 at 9:52 PM

$CAPR Here are the gory details of the WSJ article. Sadly this FDA is just a political clown show

6 · Reply

aladdinscarpet Feb. 25 at 9:39 PM

$CAPR https://www.wsj.com/opinion/vinay-prasad-fda-drug-approvals-disc-medicine-regenxbio-marty-makary-8488f514?st=P7AvEn&reflink=desktopwebshare_permalink

0 · Reply

BioResearcher Feb. 25 at 9:34 PM

$LRMR $CAPR $CPIX $SRPT Glad I found LRMR, another hidden gem like CPIX, early!

0 · Reply

Cote0924 Feb. 25 at 9:20 PM

$CAPR Things still looking bleak over at Srpt https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2025

0 · Reply

Market Cap	1.28B
Revenue (ttm)	22.27M
Net Income (ttm)	-40.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	44.85
Profit Margin	-181.72%
Debt to Equity Ratio	0.00

Volume	527,800
Avg Vol	1,225,344
Day's Range	N/A - N/A
Shares Out	45.72M
Stochastic %K	86%
Beta	0.38
Analysts	Strong Sell
Price Target	$50.80